Revance Therapeutics Inc (RVNC)
3.31
-0.98
(-22.84%)
USD |
NASDAQ |
May 10, 16:00
3.31
0.00 (0.00%)
After-Hours: 19:50
Revance Therapeutics Cash from Operations (Quarterly): -42.73M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -42.73M |
| September 30, 2023 | -50.96M |
| June 30, 2023 | -53.38M |
| March 31, 2023 | -69.50M |
| December 31, 2022 | -30.18M |
| September 30, 2022 | -57.87M |
| June 30, 2022 | -44.22M |
| March 31, 2022 | -61.27M |
| December 31, 2021 | -44.61M |
| September 30, 2021 | -53.17M |
| June 30, 2021 | -49.00M |
| March 31, 2021 | -74.76M |
| December 31, 2020 | -62.31M |
| September 30, 2020 | -55.69M |
| June 30, 2020 | -17.21M |
| March 31, 2020 | -43.29M |
| December 31, 2019 | -33.51M |
| September 30, 2019 | -31.95M |
| June 30, 2019 | -29.29M |
| March 31, 2019 | -11.41M |
| December 31, 2018 | -31.14M |
| September 30, 2018 | -25.40M |
| Date | Value |
|---|---|
| June 30, 2018 | -36.56M |
| March 31, 2018 | -11.14M |
| December 31, 2017 | -28.40M |
| September 30, 2017 | -21.46M |
| June 30, 2017 | -24.29M |
| March 31, 2017 | -21.19M |
| December 31, 2016 | -13.47M |
| September 30, 2016 | -14.35M |
| June 30, 2016 | -16.33M |
| March 31, 2016 | -15.68M |
| December 31, 2015 | -16.45M |
| September 30, 2015 | -13.71M |
| June 30, 2015 | -12.49M |
| March 31, 2015 | -13.03M |
| December 31, 2014 | -9.122M |
| September 30, 2014 | -12.69M |
| June 30, 2014 | -12.15M |
| March 31, 2014 | -21.11M |
| December 31, 2013 | -13.98M |
| September 30, 2013 | -6.473M |
| June 30, 2013 | -20.72M |
| March 31, 2013 | -6.583M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-74.76M
Minimum
Mar 2021
-17.21M
Maximum
Jun 2020
-47.63M
Average
-49.00M
Median
Jun 2021
Cash from Operations (Quarterly) Benchmarks
| AbbVie Inc | 4.04B |
| Alnylam Pharmaceuticals Inc | -81.52M |
| Ionis Pharmaceuticals Inc | -149.94M |
| Madrigal Pharmaceuticals Inc | -149.16M |
| Vertex Pharmaceuticals Inc | 1.307B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 2.37M |
| Cash from Financing (Quarterly) | -1.629M |
| Free Cash Flow | -223.46M |
| Free Cash Flow Per Share (Quarterly) | -0.5119 |
| Free Cash Flow to Equity (Quarterly) | -45.25M |
| Free Cash Flow to Firm (Quarterly) | -42.55M |
| Free Cash Flow Yield | -79.80% |